• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed

    2/16/21 4:07:45 PM ET
    $GNMK
    Medical/Dental Instruments
    Health Care
    Get the next $GNMK alert in real time by email
    SC 13G 1 tm215825d14_sc13g.htm SCHEDULE 13G

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    Genmark Diagnostics, Inc.

    (Name of Issuer)

     

    Common Stock, $0.0001 par value

    (Title of Class of Securities)

     

    372309104 

    (CUSIP Number)

     

    December 31, 2020

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    þRule 13d-1(b)

     

    oRule 13d-1(c)

     

    oRule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 372309104

    1

    Name of Reporting Person

     

    Redmile Group, LLC

    2

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) ¨

     

    (b) ¨

    3

    SEC Use Only

     

    4

    Citizenship or Place of Organization

     

    Delaware

     

     

     

    number of
    shares
    beneficially
    owned by
    each
    reporting
    person with

     

     

    5

    Sole Voting Power

     

    0

    6

    Shared Voting Power

     

    4,537,400 (1)

     

    7

    Sole Dispositive Power

     

    0

    8

    Shared Dispositive Power

     

    4,537,400 (1)

     

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    4,537,400 (1)

     

    10

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

     

    11

    Percent of Class Represented by Amount in Row (9)

     

    6.3%(2)

     

    12

    Type of Reporting Person (See Instructions)

     

    IA, OO

           

     

    (1) Redmile Group, LLC’s beneficial ownership of the Issuer’s Common Stock (“Common Stock”) is comprised of 4,537,400 shares of Common Stock owned by certain private investment vehicles and/or separately managed accounts managed by Redmile Group, LLC, which shares of Common Stock may be deemed beneficially owned by Redmile Group, LLC as investment manager of such private investment vehicles and/or separately managed accounts. The reported securities may also be deemed beneficially owned by Jeremy C. Green as the principal of Redmile Group, LLC. Redmile Group, LLC and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any.

    (2) Percentage based on 71,721,004 shares of Common Stock outstanding as of October 23, 2020, as reported by the Issuer in its Form 10-Q for the quarterly period ended September 30, 2020 filed with the Securities and Exchange Commission on October 28, 2020 (the “Form 10-Q”).

     

     

     

     

    CUSIP No. 372309104

     

    1

    Name of Reporting Person

     

    Jeremy C. Green

    2

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) ¨

     

    (b) ¨

    3

    SEC Use Only

     

     

    4

    Citizenship or Place of Organization

     

    United Kingdom

     

     

     

     

    number of shares beneficially owned by each reporting person with

     

     

    5

    Sole Voting Power

     

    0

    6

    Shared Voting Power

     

    4,537,400 (3)

     

    7

    Sole Dispositive Power

     

    0

    8

    Shared Dispositive Power

     

    4,537,400 (3)

     

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    4,537,400 (3)

    10

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

    11

    Percent of Class Represented by Amount in Row (9)

     

    6.3%(4)

    12

    Type of Reporting Person (See Instructions)

     

    IN, HC

           

     

    (3) Jeremy C. Green’s beneficial ownership of Common Stock is comprised of 4,537,400 shares of Common Stock owned by certain private investment vehicles and/or separately managed accounts managed by Redmile Group, LLC, which shares of Common Stock may be deemed beneficially owned by Redmile Group, LLC as investment manager of such private investment vehicles and/or separately managed accounts. The reported securities may also be deemed beneficially owned by Jeremy C. Green as the principal of Redmile Group, LLC. Redmile Group, LLC and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any.

    (4) Percentage based on 71,721,004 shares of Common Stock outstanding as of October 23, 2020, as reported by the Issuer in the Form 10-Q.

     

     

     

     

    Item 1.

     

    (a)Name of Issuer

     

    GenMark Diagnostics, Inc.

     

    (b)Address of Issuer’s Principal Executive Offices

     

    5964 La Place Court

    Carlsbad, California 92008

     

    Item 2.

     

    (a)Names of Persons Filing

     

    Redmile Group, LLC
    Jeremy C. Green

     

    (b)Address of Principal Business office or, if None, Residence

     

    Redmile Group, LLC
    One Letterman Drive
    Building D, Suite D3-300
    The Presidio of San Francisco
    San Francisco, California 94129

     

    Jeremy C. Green
    c/o Redmile Group, LLC
    One Letterman Drive
    Building D, Suite D3-300
    The Presidio of San Francisco
    San Francisco, California 94129

     

    (c)Citizenship

     

    Redmile Group, LLC: Delaware
    Jeremy C. Green: United Kingdom

     

    (d)Title of Class of Securities

     

    Common Stock, $0.0001 par value

     

    (e)CUSIP Number

     

    372309104

     

    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
         
    (b)¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
         
    (c)¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

     

     

     

     

    (d)¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);
         
    (e)x An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
         
    (f)¨ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
         
    (g)x A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
         
    (h)¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
         
    (i)¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
         
    (j)¨ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
         
    (k)¨ Group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: __________

     

    Item 4.Ownership.

     

    (a)Amount beneficially owned:

     

    Redmile Group, LLC – 4,537,400*
    Jeremy C. Green – 4,537,400*

     

    (b)Percent of class:

     

    Redmile Group, LLC – 6.3%**
    Jeremy C. Green – 6.3%**

     

    (c)Number of shares as to which Redmile Group, LLC has:

     

    (i)Sole power to vote or to direct the vote:

     

    0

     

    (ii)Shared power to vote or to direct the vote:

     

    4,537,400 *

     

    (iii)Sole power to dispose or to direct the disposition of:

     

    0

     

    (iv)Shared power to dispose or to direct the disposition of:

     

    4,537,400 *

     

    Number of shares as to which Jeremy C. Green has:

     

    (i)Sole power to vote or to direct the vote:

     

    0

     

     

     

     

    (ii)Shared power to vote or to direct the vote:

     

    4,537,400*

     

    (iii)Sole power to dispose or to direct the disposition of:

     

    0

     

    (iv)Shared power to dispose or to direct the disposition of:

     

    4,537,400*

     

    *Redmile Group, LLC’s and Jeremy C. Green’s beneficial ownership of the Issuer’s Common Stock is comprised of 4,537,400 shares of Common Stock owned by certain private investment vehicles and/or separately managed accounts managed by Redmile Group, LLC, which shares of Common Stock may be deemed beneficially owned by Redmile Group, LLC as investment manager of such private investment vehicles and/or separately managed accounts. The reported securities may also be deemed beneficially owned by Jeremy C. Green as the principal of Redmile Group, LLC. Redmile Group, LLC and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any.

     

    ** Percentage based on 71,721,004 shares of Common Stock outstanding as of October 23, 2020, as reported by the Issuer in the Form 10-Q.

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ¨

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    N/A.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

     

    See the response to Item 4.

     

    Item 8.Identification and Classification of Members of the Group.

     

    N/A

     

    Item 9.Notice of Dissolution of Group.

     

    N/A

     

    Item 10.Certifications.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 16, 2021

     

     

    Redmile Group, LLC 

         
      By: /s/ Jeremy C. Green
       

    Name: Jeremy C. Green

    Title: Managing Member

     

        /s/ Jeremy C. Green  
       

    Jeremy C. Green 

     

     

    Get the next $GNMK alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GNMK

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $GNMK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Gene Panel Market size worth $ 8.22 Million, Globally, by 2028 at 21.36% CAGR: Verified Market Research®

    Jersey City, New Jersey, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Verified Market Research recently published a report, "Gene Panel Market" By Technique (Amplicon-Based Approach, Hybridization-Based Approach), By Design (Predesigned Gene Panels, Customized Gene Panels), By Application (Pharmacogenetics, Diagnosis of Congenital Disorders, Cancer Risk Assessment, Others), and By Geography. According to Verified Market Research, the Global Gene Panel Market size was valued at USD 1.70 Billion in 2020 and is projected to reach USD 8.22 Billion by 2028, growing at a CAGR of 21.36% from 2021 to 2028. Download PDF Brochure: https://www.verifiedmarketresearch.com/download-sample/?rid=29123 Browse in-de

    10/13/21 11:15:00 AM ET
    $GNMK
    Medical/Dental Instruments
    Health Care

    Roche commences tender offer for all shares of GenMark Diagnostics, Inc. for $24.05 per share in cash

    Basel, 25 March 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it has commenced a cash tender offer for all of the outstanding shares of common stock of GenMark Diagnostics, Inc. (NASDAQ: GNMK) at a price of $24.05 per share. The tender offer is being made pursuant to the previously announced merger agreement dated as of March 12, 2021 among Roche Holdings, Inc., an indirect wholly owned subsidiary of Roche Holding Ltd, Geronimo Acquisition Corp., a wholly owned subsidiary of Roche Holdings, Inc., and GenMark. The tender offer period will expire at 12:00 midnight, Eastern Time, at the end of the day on Wednesday, April 21, 2021, unless the offer is extended. Roche

    3/25/21 12:40:00 PM ET
    $GNMK
    Medical/Dental Instruments
    Health Care

    Roche signs definitive merger agreement with GenMark Diagnostics, Inc., to access novel technology to test for broad range of pathogens with one patient sample

    Roche to acquire GenMark Diagnostics for US$ 24.05 per share with the expectation to close in the 2nd quarter of 2021GenMark provides molecular diagnostic tests that are designed to detect multiple pathogens from a single patient sampleGenMark’s ePlex platform delivers rapid and actionable results so clinicians can determine the cause of infection and the most effective treatment, potentially saving lives and alleviating the healthcare burden. The addition of GenMark’s proprietary multiplex technology complements Roche’s diagnostic offering, addressing a broad range of infectious disease testing needs, including respiratory and bloodstream infections              Basel, 15 March 2021 - Roc

    3/15/21 2:00:00 AM ET
    $GNMK
    Medical/Dental Instruments
    Health Care

    $GNMK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    GenMark Diagnostics downgraded by BTIG

    BTIG downgraded GenMark Diagnostics from Buy to Neutral

    3/17/21 7:31:42 AM ET
    $GNMK
    Medical/Dental Instruments
    Health Care

    GenMark Diagnostics downgraded by Cowen & Co. with a new price target

    Cowen & Co. downgraded GenMark Diagnostics from Outperform to Market Perform and set a new price target of $24.05 from $23.00 previously

    3/17/21 6:46:59 AM ET
    $GNMK
    Medical/Dental Instruments
    Health Care

    GenMark Diagnostics downgraded by Canaccord Genuity

    Canaccord Genuity downgraded GenMark Diagnostics from Buy to Hold

    3/16/21 10:34:41 AM ET
    $GNMK
    Medical/Dental Instruments
    Health Care

    $GNMK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Giles Lisa M. decreased direct ownership by 100% to 0 units to satisfy tax liability

    4 - GenMark Diagnostics, Inc. (0001487371) (Issuer)

    4/22/21 1:55:57 PM ET
    $GNMK
    Medical/Dental Instruments
    Health Care

    SEC Form 4: Fox James decreased direct ownership by 100% to 0 units to cover taxes

    4 - GenMark Diagnostics, Inc. (0001487371) (Issuer)

    4/22/21 1:55:12 PM ET
    $GNMK
    Medical/Dental Instruments
    Health Care

    SEC Form 4: Kagnoff Michael decreased direct ownership by 100% to 0 units to satisfy tax liability

    4 - GenMark Diagnostics, Inc. (0001487371) (Issuer)

    4/22/21 1:55:32 PM ET
    $GNMK
    Medical/Dental Instruments
    Health Care

    $GNMK
    SEC Filings

    View All

    SEC Form 15-12B filed by GenMark Diagnostics, Inc.

    15-12B - GenMark Diagnostics, Inc. (0001487371) (Filer)

    5/3/21 4:02:03 PM ET
    $GNMK
    Medical/Dental Instruments
    Health Care

    SEC Form EFFECT filed by GenMark Diagnostics, Inc.

    EFFECT - GenMark Diagnostics, Inc. (0001487371) (Filer)

    4/28/21 12:15:09 AM ET
    $GNMK
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 POS filed by GenMark Diagnostics, Inc.

    S-8 POS - GenMark Diagnostics, Inc. (0001487371) (Filer)

    4/22/21 4:22:52 PM ET
    $GNMK
    Medical/Dental Instruments
    Health Care

    $GNMK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by GenMark Diagnostics, Inc. (Amendment)

    SC 13G/A - GenMark Diagnostics, Inc. (0001487371) (Subject)

    5/10/21 11:58:21 AM ET
    $GNMK
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by GenMark Diagnostics, Inc. (Amendment)

    SC 13G/A - GenMark Diagnostics, Inc. (0001487371) (Subject)

    4/12/21 1:05:52 PM ET
    $GNMK
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D filed by GenMark Diagnostics, Inc.

    SC 13D - GenMark Diagnostics, Inc. (0001487371) (Subject)

    3/26/21 9:07:58 AM ET
    $GNMK
    Medical/Dental Instruments
    Health Care